These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33146794)

  • 1. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
    Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
    Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
    Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
    Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
    Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
    AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
    [No Abstract]   [Full Text] [Related]  

  • 7. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
    Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
    Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-Catenin-Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta-Analysis.
    Shen L; Altmayer S; Tse JR
    J Magn Reson Imaging; 2024 Nov; 60(5):2104-2114. PubMed ID: 38465878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Adenoma Subtypes Based on 2017 Classification System: Exploratory Study of Gadoxetate Disodium-Enhanced MRI Features With Proposal of a Diagnostic Algorithm.
    Tse JR; Felker ER; Cao JJ; Naini BV; Liang T; Lu DSK; Raman SS
    AJR Am J Roentgenol; 2023 Apr; 220(4):539-550. PubMed ID: 36169546
    [No Abstract]   [Full Text] [Related]  

  • 10. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
    Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
    Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
    Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
    Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
    Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
    Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.
    Denecke T; Steffen IG; Agarwal S; Seehofer D; Kröncke T; Hänninen EL; Kramme IB; Neuhaus P; Saini S; Hamm B; Grieser C
    Eur Radiol; 2012 Aug; 22(8):1769-75. PubMed ID: 22437921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.
    Tse JR; Naini BV; Lu DS; Raman SS
    Radiology; 2016 Apr; 279(1):118-27. PubMed ID: 26505921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background.
    Yoneda N; Matsui O; Kitao A; Kozaka K; Kobayashi S; Sasaki M; Yoshida K; Inoue D; Minami T; Gabata T
    Radiographics; 2016; 36(7):2010-2027. PubMed ID: 27740898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.